WallStSmart

Boston Scientific Corp (BSX)vsIntel Corporation (INTC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Intel Corporation generates 163% more annual revenue ($52.85B vs $20.07B). BSX leads profitability with a 14.4% profit margin vs -0.5%. INTC appears more attractively valued with a PEG of 0.50. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

INTC

Hold

42

out of 100

Grade: D

Growth: 2.0Profit: 4.0Value: 6.7Quality: 7.5
Piotroski: 5/9Altman Z: 1.69
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Intrinsic value data unavailable for INTC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

INTC3 strengths · Avg: 9.3/10
Market CapQuality
$220.09B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.5010/10

Growing faster than its price suggests

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

INTC4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.694/10

Distress zone — elevated risk

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Revenue GrowthGrowth
-4.1%2/10

Revenue declined 4.1%

EPS GrowthGrowth
-71.7%2/10

Earnings declined 71.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : INTC

The strongest argument for INTC centers on Market Cap, PEG Ratio, Price/Book. PEG of 0.50 suggests the stock is reasonably priced for its growth.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : INTC

The primary concerns for INTC are Altman Z-Score, Return on Equity, Revenue Growth.

Key Dynamics to Monitor

BSX profiles as a growth stock while INTC is a turnaround play — different risk/reward profiles.

INTC carries more volatility with a beta of 1.38 — expect wider price swings.

BSX is growing revenue faster at 15.9% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (63/100 vs 42/100) and 15.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Intel Corporation

TECHNOLOGY · SEMICONDUCTORS · USA

Intel Corporation is an American multinational corporation and technology company headquartered in Santa Clara, California, in Silicon Valley. It is the world's largest semiconductor chip manufacturer by revenue, and is the developer of the x86 series of microprocessors, the processors found in most personal computers (PCs).

Visit Website →

Want to dig deeper into these stocks?